Skip to content

Brain-injured Patients Extubation Readiness Study

Stepped Wedge Cluster Randomised Controlled Trial to Assess the Readiness of Extubation in Brain-injured Patients Using a Clinical Score

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04080440
Acronym
Biper
Enrollment
660
Registered
2019-09-06
Start date
2020-02-09
Completion date
2027-10-13
Last updated
2025-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Brain Injury, Airway Control, Altered Level of Consciousness, Mechanical Ventilation, Mechanical Ventilator Weaning

Keywords

Coma, Intensive care units, Critical care, Stroke, Traumatic brain injury, Anoxic ischemic encephalopathy, Glasgow coma scale

Brief summary

The BIPER study is a stepped wedge cluster randomised clinical trial aiming to decrease extubation failure in critically-ill brain-injured patients with residual impaired consciousness using a simple clinical score.

Detailed description

Severe brain-injured patients need mechanical ventilation with tracheal intubation. After treatment of the acute neurological condition, weaning of the mechanical ventilation has to be initiated notably to prevent ventilator associated pneumonia and others complications. Nevertheless, extubation failure is very common in this population due to residual neurological impairment with airway control alteration. Guidelines about weaning of mechanical ventilation and extubation exclude brain-injured patients with a residual impaired consciousness. In 2017, a simple and pragmatic extubation readiness clinical score was validated in a prospective observational cohort study of 140 brain injured patients. (Godet et al. Anesthesiology. 2017 Jan;126(1):104-114) In this study, brain injured patients with residual impaired consciousness who succeeded a spontaneous breathing trial were extubated. In multivariate analysis, 4 clinical elements were associated with extubation success. A prediction score was determined using the odds ratio such as followed : 1. Deglutition: 3 points if present 2. Gag reflex: 4 points if present 3. Cough: 4 points if present 4. CRS-R Score, visual item \>2, 3 points if present, 1 point if not For a cut-off value of 9, extubation failure could be predicted with a sensibility of 84%, a specificity of 75%, a positive predictive value of 89% and a negative predictive value of 66%. In order to participate, brain-injured patients will have to succeed a spontaneous breathing trial and meet all inclusion criteria, including not being able to obey to command with no or minimal sedation. Using a stepped wedge randomisation process with intensive care units as clusters, patients will be weaned and extubated under usual care or using the extubation readiness clinical score. The authors' hypothesis is that this clinical score will allow physicians to extubate patients at the right time interval and prevent extubation failure in this frail population.

Interventions

PROCEDUREExtubation readiness clinical score

After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day. In the intervention group, after a successful spontaneous breathing trial in unconscious patients, the score will be evaluated. If the score is \> 9, extubation has to be completed.

PROCEDUREUsual Care

After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day. In the control group, after a successful spontaneous breathing trial in unconscious patients, the extubation will be achieved according to usual care.

Sponsors

ANARLF Network
CollaboratorUNKNOWN
Direction Générale de l'Offre de Soin (DGOS)
CollaboratorUNKNOWN
University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Stepped wedge, cluster randomised controlled design

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Acute cerebral lesion with a Glasgow Coma Scale \<13 needing admission in ICU and mechanical ventilation with tracheal intubation for neurological cause : cerebrovascular stroke either ischemic or hemorrhagic including aneurysmal subarachnoid hemorrhage, traumatic brain injury, anoxo ischemic encephalopathy after cardiac arrest or brain tumour * Mechanical ventilation more than 48 hours * 18 to 75 years old * Neurological stability with no intracranial hypertension with minimal sedation * Glasgow Coma Scale motor response \< 6 * Spontaneous breathing trial succeeded * First extubation attempt

Exclusion criteria

* Posterior cranial fossa lesion * Admission for status epilepticus or central nervous system infection * Spinal cord injury (tetraplegia or paraplegia) * Uncontrolled status epilepticus or uncontrolled central nervous system infection * Care limitation plan * Chronic respiratory failure defined as ambulatory oxygen therapy or pressure support ventilation and/or proven COPD and/or ambulatory non-invasive CPAP therapy for sleep apnoea syndrome * More than 3 failed spontaneous breathing trials * Significant chest trauma (more than 2 broken ribs / broken sternum / with an indication of open thoracic surgery) * Surgery planned within 7 days * Tracheotomy or previous extubation outside of the protocol * Previous compromised upper airway permeability * Pregnant or breastfeeding woman * Adult under the protection of the law or without social assurance system * Inclusion in another clinical study about mechanical ventilation or weaning

Design outcomes

Primary

MeasureTime frameDescription
Extubation failureFrom extubation to Day 5 (120 hours) after extubationExtubation failure is defined as a need of reintubation or death in the 5 days (120 hours) following extubation

Secondary

MeasureTime frameDescription
Invasive mechanical ventilation durationFrom admission to the end of ICU StayPeriod expressed in days during which patients will need invasive mechanical ventilation
Non-invasive mechanical ventilation durationFrom admission to the end of ICU StayPeriod expressed in days during which patients will need non-invasive mechanical ventilation
Reintubation rate in the first 48 hoursFrom extubation to Day 2 after extubation (48 hours)Patients needing reintubation during the first 48h post-extubation
Reintubation rate in ICUFrom extubation to the end of ICU StayPatients needing reintubation during entire ICU stay
Post extubation nosocomial pneumoniaFrom extubation to the end of ICU stayPost extubation nosocomial pneumonia is defined as a pulmonary infection after extubation that necessitate antibiotic therapy
Tracheotomy after extubationFrom extubation to the end of ICU StayNumber of patients that necessitate a tracheotomy after extubation failure
Key secondary outcome measure: time to effective extubationFrom enrollment to day 5 (120 hours) after extubationTime from SBT success (enrollment) to successful liberation from mechanical ventilation, defined as the time point at which a patient is alive and free of invasive ventilatory support for more than 5 days (120 hours)
ICU length of stayFrom admission to the end of ICU StayICU length of stay expressed in days
Hospital length of stayFrom admission to the end of Hospital StayHospital length of stay expressed in days
Mortality in ICUFrom enrollment to the end of the ICU StayDeceased patient in each group during ICU stay
Mortality at day 28From enrollment to Day 28Deceased patient in each group at day 28
Mortality at day 90From enrollment to Day 90Deceased patient in each group at day 90
Neurological outcomeDay 90 after enrollmentNeurological outcome using the Glasgow Outcome Scale Extended
Tracheotomy before extubationFrom enrollment to the end of ICU StayNumber of patients that necessitate a tracheotomy after a successful spontaneous breathing trial but before any extubation

Countries

France

Contacts

Primary ContactLise Laclautre
promo_interne_drci@chu-clermontferrand.fr+33 4 73 754963

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026